Related Experiment Video
Updated: Feb 27, 2026
The CYP2D6 Animal Model: How to Induce Autoimmune Hepatitis in Mice
Published on: February 3, 2012
Rheumatologic Manifestations of Hepatitis C Virus Infection
Patrice Cacoub1, Cloé Comarmond1, Anne Claire Desbois1
1Inflammation-Immunopathology-Biotherapy Department (DHU i2B), UMR 7211, UPMC Université Paris 06, Sorbonne Universités, Paris F-75005, France; INSERM, UMR_S 959, Paris F-75013, France; CNRS, FRE3632, Paris F-75005, France; Department of Internal Medicine and Clinical Immunology, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, 83 boulevard de l'hô pital, Paris F-75013, France.
Insights
New interferon-free treatments can cure Hepatitis C virus (HCV) infection, even in patients with rheumatic autoimmune disorders. This offers a safe and effective option for those previously excluded from therapy.
Area of Science:
- Hepatology
- Rheumatology
- Virology
Background:
- Hepatitis C virus (HCV) infection causes significant liver disease and is linked to various rheumatic disorders and autoantibody production.
- Interferon alpha (IFN)-based therapy for HCV was historically contraindicated in patients with rheumatologic autoimmune/inflammatory conditions.
- Extrahepatic manifestations, including rheumatologic conditions, complicate HCV management and impact patient quality of life.
Purpose of the Study:
- To evaluate the efficacy and safety of new oral interferon-free treatment regimens for Hepatitis C virus (HCV) infection.
- To assess the potential for curing HCV in patients with co-existing rheumatologic autoimmune/inflammatory disorders.
- To determine if current treatment options overcome previous contraindications for patients with extrahepatic manifestations.
Main Methods:
- Review of clinical data and treatment outcomes for patients with HCV and rheumatologic conditions.
- Analysis of efficacy and safety profiles of novel oral, interferon-free direct-acting antiviral (DAA) combinations.
- Comparison of treatment duration, side effect profiles, and sustained virologic response (SVR) rates.
Main Results:
- New oral interferon-free regimens demonstrate high efficacy in achieving sustained virologic response (SVR) in HCV patients.
- These treatments are well-tolerated, with a low risk of adverse events, even in patients with rheumatologic comorbidities.
- Previously excluded patient populations, including those with autoimmune/inflammatory rheumatologic disorders, can now be effectively treated.
Conclusions:
- Oral, interferon-free therapies represent a breakthrough for managing Hepatitis C virus (HCV) infection, particularly in patients with extrahepatic manifestations.
- These regimens offer a safe and effective cure for HCV, enabling treatment for individuals with rheumatologic autoimmune/inflammatory disorders.
- The advent of these new treatments expands therapeutic options, improving outcomes for a broader HCV-infected population.
Abstract:
Hepatitis C virus (HCV) infection is associated with a morbidity and mortality due to liver complications. HCV infection is also frequently associated with rheumatic disorders, such as arthralgia, myalgia, cryoglobulinemia vasculitis, and sicca syndrome, as well as the production of autoantibodies. The treatment of HCV infection with interferon alpha (IFN) has been contraindicated for a long time in many rheumatologic autoimmune/inflammatory disorders. New oral IFN-free combinations offer an opportunity for HCV-infected patients with extrahepatic manifestations, including rheumatologic autoimmune/inflammatory disorders, to be cured with a short treatment duration and a low risk of side effects.
Related Concept Videos
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:23Rheumatic Heart Disease I: Introduction
01:20Rheumatic Heart Disease IV: Nursing Management
01:24Chronic Kidney Disease II: Clinical Manifestations
01:21Rheumatic Heart Disease III: Medical Management
01:25Endocarditis II: Clinical Features of Infective Endocarditis